278 results on '"Chng, W"'
Search Results
2. RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC
3. Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore
4. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group
5. Gene signature combinations improve prognostic stratification of multiple myeloma patients
6. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
7. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib
8. P1573: VARIATION IN USE OF IMMUNOGLOBULIN AND IMPACT ON SURVIVAL IN MULTIPLE MYELOMA: A REPORT FROM THE AUSTRALIA/NEW ZEALAND (ANZ) AND ASIA-PACIFIC (APAC) MYELOMA AND RELATED DISEASES REGISTRIES (MRDR)
9. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
10. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
11. Cbfb deficiency results in differentiation blocks and stem/progenitor cell expansion in hematopoiesis
12. P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
13. p53 haploinsufficiency and functional abnormalities in multiple myeloma
14. Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group
15. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
16. IMWG consensus on risk stratification in multiple myeloma
17. JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma
18. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype
19. Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma
20. DIGITAL SPATIAL PROFILING OF DIFFUSE LARGE B‐CELL LYMPHOMAS REVEALS STING AS AN IMMUNE‐RELATED DETERMINANT OF SURVIVAL AFTER R‐CHOP THERAPY
21. CLINICAL APPLICATION OF AN EX‐VIVO PLATFORM TO GUIDE THE CHOICE OF DRUG COMBINATIONS IN RELAPSED/REFRACTORY LYMPHOMA; A PROSPECTIVE STUDY
22. Management of treatment-emergent peripheral neuropathy in multiple myeloma
23. 852P c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
24. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
25. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma
26. Clinical and biological significance of RAS mutations in multiple myeloma
27. Genetic aberrations and survival in plasma cell leukemia
28. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
29. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: The phase III TOURMALINE-MM4 trial
30. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
31. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations
32. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
33. Erratum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
34. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature
35. Proteomic Analysis of Multiple Myeloma Identifies Upregulation of the Novel Protein CRIK: B539
36. Clinical significance of TP53 mutation in myeloma
37. Do β2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?
38. IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma
39. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
40. PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL--ANALYSIS FROM THE TOURMALINE-MM3 STUDY
41. Haematological parameters in severe acute respiratory syndrome
42. Leukaemic infiltration of the choroid
43. t(8;14) Mature B-cell (Burkittʼs) lymphoma/leukaemia with atypical morphology in a paediatric patient
44. Unusual presentation of neutrophilic eccrine hidradenitis
45. Pel-Ebstein fever with cyclical pancytopenia
46. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
47. Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study
48. WHOLE-GENOME SEQUENCING REVEALS IMMUNOTHERAPEUTIC OPTIONS FOR NATURAL-KILLER/T CELL LYMPHOMA PATIENTS
49. PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL – ANALYSIS FROM THE TOURMALINE-MM3 STUDY
50. ABERRANT HYPEREDITING OF MYELOMA TRANSCRIPTOME BY ADAR1 CONFERS ONCOGENICITY AND IS A MARKER OF POOR PROGNOSIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.